| Drug Name | GPCR-targeted Project 011 |
| Description |
A monoclonal antibody agonist the G -protein coupled receptor G2A (GRP132) is being developed for the treatment of pancreatic cancer and pancreatic cancer ductal adenocarcinoma. GPR132 is a novel member of GPCRs. |
| Target | G-protein coupled receptor G2A (GRP132) |
| Drug Modality | Monoclonal antibody |
| Indication | Pancreatic cancer |
| Product Category | Biologic |
| Mechanism of Action | G protein-coupled receptor agonists |
| Status | Discovery |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |